Plain-English answer
U.S. healthcare companies entering China need to translate a U.S. operating model into a Chinese policy, payment, and hospital environment. FDA clearance, U.S. payer traction, or hospital reference accounts can help credibility, but China still requires local regulatory classification, Chinese-language documentation, local clinical or bridging evidence where needed, hospital procurement access, and a price strategy that can survive public-sector cost controls.
Market context
For drugs, the 2019 Drug Administration Law and 2020 registration reforms institutionalized tools such as the marketing authorization holder system, priority review, conditional approval, and breakthrough therapy procedures. For devices, NMPA registration reviews safety, effectiveness, and quality management, with separate pathways for clinical evaluation, priority registration, and emergency registration. The question for a U.S. company is not whether China recognizes innovation; it is whether the company can produce the evidence and operating commitments China asks for.
Payment is often the second shock. The NHSA's annual NRDL negotiations and centralized procurement programs can expand access while compressing prices. Public hospitals are powerful demand nodes, but they operate under procurement platforms, budget controls, DRG/DIP payment reform, and anti-corruption scrutiny. U.S. commercial playbooks built around premium pricing and local sales discretion usually need substantial adjustment.
Operating model
U.S. firms should build a China readiness file before selecting partners: regulatory status and classification, China-specific claims, evidence gaps, import and labeling requirements, quality system obligations, data flows, distribution needs, reimbursement assumptions, target hospitals, and adverse-event or post-market responsibilities. Digital health and AI firms need an additional data map covering personal information, sensitive medical information, data localization, cross-border transfers, model training data, and hospital system integration.
Partner selection should follow the pathway map. A distributor may be enough for a low-risk, self-pay device with simple servicing. It is rarely enough for a therapy requiring physician education, hospital formulary access, NRDL strategy, cold-chain logistics, patient assistance, or real-world evidence. The partner's government affairs claims should be checked against actual provincial platform access, hospital accounts, compliance record, and technical service capacity.
Strategic reading
The strongest U.S. entrants localize the proposition without surrendering the core asset. That may mean China-specific health-economic evidence, Chinese clinical sites, local manufacturing or final assembly, a domestic licensee, or a staged launch in selected provinces. It does not mean handing over IP, data rights, or regulatory control casually.
For board-level decisions, China should be modeled as a sequence of gates: legal viability, regulatory approvability, payment fit, hospital adoption, compliance durability, and partner control. Failure at any gate can make a promising market mathematically large but commercially weak.
Implementation detail
U.S. companies should prepare a China translation of their value proposition. U.S. claims about FDA clearance, health-system savings, or physician productivity need to be restated in terms Chinese regulators, hospitals, and payers can use. That may mean China epidemiology, Chinese workflow, Chinese comparator products, and Chinese hospital payment effects.
The internal team should also include legal, privacy, regulatory, quality, medical affairs, finance, and supply chain from the beginning. China market entry touches all of those functions; if only business development owns the project, the company may discover the hard constraints too late.